Can Fresh Capital Strengthen Growth Pipelines Across Healthcare and Energy Plays?

Source: Kapitales Research

Highlights:

·      Atomo Diagnostics  is undertaking a capital raise of up to AU$4.0 million via placement and share purchase plan to support commercial expansion.

·      Blue Star Helium has secured AU$10.0 million through an oversubscribed institutional placement to advance key helium projects.

·      Both companies are directing funds toward scaling operations and advancing core assets, reflecting a focus on execution-driven growth strategies.

Atomo Diagnostics Advances Commercialisation with Capital Raise

Atomo Diagnostics (ASX: AT1) is raising up to AU$4.0 million, comprising a AU$3.0 million placement and a share purchase plan (SPP) of up to AU$1.0 million. The placement involves issuing approximately 90.9 million shares at AU$0.033 per share, along with attaching options on a one-for-two basis. Atomo Diagnostics was trading at AU$0.031, reflecting a ~22.5% decline, indicating a cautious market response to the capital raising.

How Will the Funds Be Used: The proceeds are intended to support commercial expansion of Atomo’s diagnostic portfolio, including products such as syphilis and liver function tests, while also enabling operational scale-up and working capital support.

Blue Star Helium Secures Funding to Advance Key Projects

Blue Star Helium (ASX: BNL) has raised AU$10.0 million through an institutional placement of approximately 1.67 billion shares at AU$0.006 per share, with strong participation from institutional and sophisticated investors. The placement is structured in two phases, where an initial portion will be issued using the company’s current capacity, while the balance will require approval from shareholders. Blue Star Helium was trading at AU$0.009, showing ~0% change, suggesting a neutral market reaction despite the successful capital raise.

Where Will the Funds Be Deployed: The capital will be used to advance the Galactica and Pegasus projects, alongside supporting general working capital requirements.

Outlook

• Atomo Diagnostics is positioning itself to scale its global diagnostic offerings, with the capital raise expected to support both product commercialisation and operational capacity expansion.
• Blue Star Helium is focused on progressing its helium asset base, with funding aimed at increasing production capacity and advancing project timelines.

Both companies are utilising fresh capital to strengthen execution across their respective sectors, with outcomes likely to depend on delivery against stated operational milestones.

 Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au